STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Biogen reported mixed Phase‑2 results for its tau‑targeting Alzheimer’s drug diranersen (BIIB080).
- Diranersen lowered tau protein levels in cerebrospinal fluid and brain tissue of early‑stage Alzheimer’s patients, and these reductions correlated with a slower rate of cognitive decline.
- Dose‑response testing across three escalating regimens showed the lowest dose produced the strongest effect, while higher doses were less effective.
- Study failed to meet its primary efficacy endpoint of a dose‑response relationship, meaning the trial did not achieve its main goal.
Why it matters: Biogen’s Alzheimer’s program faces a setback as the Phase‑2 trial, which tested three dosing regimens, missed its primary efficacy goal, delaying further development and potentially affecting the company’s pipeline timeline.
Ask SkimNews
